XML 34 R24.htm IDEA: XBRL DOCUMENT v3.21.2

Revenue - Additional Information (Detail) - Visen Pharmaceuticals [Member] $ in Millions	6 Months Ended
	Jun. 30, 2021 USD ($)
Disclosure of operating segments [line items]
Upfront payment received non cash consideration towards license revenue	$ 40.0
Percentage of ownership in the customer company	50.00%
Retained percentage of issued and outstanding shares	44.00%

X

- Definition

Retained percentage of issued and outstanding shares.

+ References

No definition available.

+ Details

Name:	asnd_RetainedPercentageOfIssuedAndOutstandingShares
Namespace Prefix:	asnd_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Upfront payment received non cash consideration towards license revenue.

+ References

No definition available.

+ Details

Name:	asnd_UpfrontPaymentReceivedNonCashConsiderationTowardsLicenseRevenue
Namespace Prefix:	asnd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.

+ References

No definition available.

+ Details

Name:	ifrs-full_DisclosureOfOperatingSegmentsLineItems
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2020-01-01
-Paragraph 17
-Subparagraph b
-Clause iii
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2020-en-r&anchor=para_17_b_iii&doctype=Standard
-URIDate 2020-01-01

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2020-01-01
-Paragraph 16
-Subparagraph b
-Clause iii
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2020-en-r&anchor=para_16_b_iii&doctype=Standard
-URIDate 2020-01-01

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2020-01-01
-Paragraph 21
-Subparagraph a
-Clause iv
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_21_a_iv&doctype=Standard
-URIDate 2020-01-01

+ Details

Name:	ifrs-full_ProportionOfOwnershipInterestInAssociate
Namespace Prefix:	ifrs-full_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	ifrs-full_MajorCustomersAxis=asnd_VisenPharmaceuticalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: